Cargando…

JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are responsive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, NSCLC patients with secondary somatic EGFR mutations are resistant to EGFR-TKI treatment. In this study, we investigated the effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fu-quan, Yang, Wen-tao, Duan, Shan-zhou, Xia, Ying-chen, Zhu, Rong-ying, Chen, Yong-bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546470/ https://www.ncbi.nlm.nih.gov/pubmed/25869210

Ejemplares similares

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
por: Huang, Keqiang, et al.
Publicado: (2018)

K(Ca) channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
por: Glaser, Felix, et al.
Publicado: (2021)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
por: Stanam, Aditya, et al.
Publicado: (2016)

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
por: Wang, Xiaofei, et al.
Publicado: (2017)

The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway
por: Liao, Jinrong, et al.
Publicado: (2020)

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms
por: Huang, Shih-Min A., et al.
Publicado: (2014)

The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling
por: Cheng, Zhao, et al.
Publicado: (2017)

The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis
por: Zhang, Yang, et al.
Publicado: (2021)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
por: Han, Shu-Yan, et al.
Publicado: (2017)

Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway
por: Chen, Liwen, et al.
Publicado: (2018)

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
por: Weigert, Oliver, et al.
Publicado: (2012)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

Enhanced PKCδ and ERK Signaling Mediate Cell Migration of Retinal Pigment Epithelial Cells Synergistically Induced by HGF and EGF
por: Chen, Yu Jung, et al.
Publicado: (2012)

Immunization With a DNA Vaccine Cocktail Encoding TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 Genes Protects Mice Against Chronic Toxoplasmosis
por: Zhang, Nian-Zhang, et al.
Publicado: (2018)

Interdependence of JAK-STAT and MAPK signaling pathways during EGF-mediated HTR-8/SVneo cell invasion
por: Malik, Ankita, et al.
Publicado: (2017)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
por: Monteleone, Nicholas J., et al.
Publicado: (2020)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
por: Romero-Ventosa, Elena Yaiza, et al.
Publicado: (2015)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity
por: Bao, Bin, et al.
Publicado: (2017)

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
por: Chen, Donglai, et al.
Publicado: (2018)

HB-EGF Activates the EGFR/HIF-1α Pathway to Induce Proliferation of Arsenic-Transformed Cells and Tumor Growth
por: Wang, Lin, et al.
Publicado: (2020)

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
por: Greve, Gabriele, et al.
Publicado: (2015)

Cell-Based Sensors for the Detection of EGF and EGF-Stimulated Ca(2+) Signaling
por: Lee, Euiyeon, et al.
Publicado: (2023)

Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Phan, Ai N.H., et al.
Publicado: (2016)

Identification of Chinese Herbal Compounds with Potential as JAK3 Inhibitors
por: Su, Dan, et al.
Publicado: (2019)

MicroRNAs Are Part of the Regulatory Network that Controls EGF Induced Apoptosis, Including Elements of the JAK/STAT Pathway, in A431 Cells
por: Alanazi, Ibrahim, et al.
Publicado: (2015)

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
por: Li, Shuyu D., et al.
Publicado: (2017)

Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
por: Ngan, Hoi-Lam, et al.
Publicado: (2020)

JAK inhibitors in systemic juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7e4sulso2ftrh7fb3ioi47o6pk